Stifel analyst Paul Matteis said Alexion's U.S. pricing for Ultomiris is below what he had modeled and it does not appear to him that sell-side numbers align with the company's conservative pricing strategy, leading him to tell investors that "Street numbers will need to come down to incorporate a new reality." However, he also sees "two major positives" from the pricing decision: namely that it should provide a "huge" tailwind for Soliris-to-Ultomiris conversions and that the company should earn "valuable brand equity" with payors. Matteis keeps a Hold rating on Alexion shares.